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Abstract: Ethanol abuse is a common issue in individuals with sedentary lifestyles, unbalanced diets,
and metabolic syndrome. Both ethanol abuse and metabolic syndrome have negative impacts on
the central nervous system, with effects including cognitive impairment and brain oxidative status
deterioration. The combined effects of ethanol abuse and metabolic syndrome at a central level have
not yet been elucidated in detail. Thus, this work aims to determine the effects of ethanol intake on a
mouse model of metabolic syndrome at the behavioral and biochemical levels. Seven-week-old male
control (B6.V-Lep ob/+JRj) and leptin-deficient (metabolic syndrome) (B6.V-Lep ob/obJRj) mice were
used in the study. Animals were divided into four groups: control, ethanol, obese, and obese–ethanol.
Ethanol consumption was monitored for 6 weeks. Basal glycemia, insulin, and glucose overload
tests were performed. To assess short- and long-term memory, an object recognition test was used.
In order to assess oxidative status in mouse brain samples, antioxidant enzyme activity was analyzed
with regard to glutathione peroxidase, glutathione reductase, glutathione, glutathione disulfide,
lipid peroxidation products, and malondialdehyde. Ethanol intake modulated the insulin response
and impaired the oxidative status in the ob mouse brain.
Keywords: ethanol; diabetes; metabolic syndrome; oxidative stress; mice
1. Introduction
According to the latest World Health Organization report on ethanol and health,
more than 2.3 billion people are heavy ethanol consumers. Ethanol abuse has high social
economic costs due to its elevated mortality and morbidity. In the European region alone,
ethanol consumption is responsible for 10% of total deaths every year [1].
Ethanol abuse is related to obesity and an increased risk of metabolic syndrome (MS)
and type 2 diabetes mellitus (T2D) [2]. MS occurs when different metabolic risk factors
such as dyslipidemia, arterial hypertension, obesity, insulin resistance, and hyperinsulin-
ism converge [3]. MS-elicited insulin resistance leads to impaired glucose homeostasis,
which has been defined as a key mechanism involved in the pathogenesis of T2D [2,4–7].
Moreover, several factors such as diet, lifestyle, physical activity, mental health, and ethanol
abuse interact with regard to the risk of suffering both pathologies [8–10]. In this respect,
it has been demonstrated that high levels of ethanol consumption play a critical role in
developing insulin resistance [11]. In fact, the World Health Organization has considered
T2D to be a complication of ethanol abuse [1].
Chronic ethanol consumption threatens the oxidative defense of the organism and
promotes the activation of different inflammatory processes which are related to the onset
of MS [12], neurodegenerative damage [13,14], and beta cell death through activation
of reactive oxygen species (ROS) [15,16]. Interestingly, some authors have described a
paradoxical effect, and demonstrated how moderate ethanol consumption can modulate
and improve insulin response in T2D [17,18]. Schaller and coworkers studied the effect of
high ethanol consumption in T2D patients and observed an increase in the insulin response
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which modulates T2D [19–28]. One of the molecular mechanisms involves an ethanol-
dependent increase in cAMP intracellular levels through a Ca2+-dependent mechanism.
The intracellular calcium release elicited by ethanol thus boosts cellular insulin levels [29,30].
However, the mechanisms underlying the connection between T2D, MS, and ethanol abuse
remain to be fully clarified.
On the other hand, it is widely known that ethanol metabolism is related to ROS
production and mitochondrial injury, which are common features of acute and chronic
ethanol exposure [31,32]. Via the dehydrogenase and microsomal ethanol oxidizing system,
this ethanol-oxidative process generates NADH or NADP+. There is a subsequent increase
in ROS levels, with the resultant oxidative stress representing an important threat to the
oxidative system of the cell. Oxidative stress is also strongly correlated with prevalence
of T2D and oxidative stress-induced tissue damage. Levels of different biomarkers such
as 4-hydroxy-2-nonenal and malondialdehyde (MDA) as well as DNA base oxidation
have been reported to be increased in the pancreatic tissue, plasma, and serum of T2D
patients [32,33]. Moreover, it has been proven that the total antioxidant cellular defense is
significantly diminished in T2D due to reduced levels of antioxidant metabolites such as
catalase, superoxide dismutase, and the glutathione system, or nonenzymatic components
such as vitamins C and E [32,34,35].
In this work, we aimed to evaluate the effect of chronic ethanol administration on
a mouse model of MS, with a special focus on oxidative balance. Of the various animal
models available for the study of MS, leptin-deficient mice (B6.Cg-LepOb) were chosen.
These are known as ob mice and are homozygous for the leptin mutation, exhibiting obesity,
hyperphagia, transient hyperglycemia, glucose intolerance, and elevated plasma insulin.
The effects of chronic ethanol administration on the central nervous system were
determined through an object recognition test to ascertain cognitive impairment with
regard to short- and long-term memory. The presence of cellular oxidative injury was
determined using a battery of oxidative status parameters including the antioxidants
glutathione reductase (GR), glutathione peroxidase (GPx), glutathione (GSH), glutathione
disulfide (GSSG), and L-cysteine. Malondialdehyde (MDA) was used as a measure to study
lipid peroxidation damage to macromolecules.
2. Results
2.1. Effects of Ethanol Intake with Regard to Weight, Glucose Overdose, Insulin, and Basal Glycemia
In order to monitor weight changes elicited by chronic ethanol consumption, we mon-
itored the weights of the mice over the course of the experiment. A two-way ANOVA
showed significant differences between the wild-type (C, E) and MS groups (Ob, Ob-E)
(p < 0.05, Figure 1a).
Glycemic status was monitored weekly. Significant differences were found by a two-
way ANOVA between the wild-type (C, E) and MS mice groups (Ob, Ob-E) in week 1.
The Ob-E group presented significantly reduced glycemia values when compared to the
Ob control group from weeks 2–6 (p < 0.05, Figure 1b).
One-way ANOVA yielded significant differences in blood insulin concentrations
between the wild-type (C, E) and MS mice groups (Ob, Ob-E) groups (p < 0.05, Figure 1c),
with greater insulinemia found in the Ob and Ob-E groups.
Figure 1d depicts increased blood glucose levels (% t0) at 30, 60, and 120 min with
respect to basal glycemia (time 0 min) over the course of the glucose overload test. A two-
way ANOVA showed significant differences between the MS (Ob and Ob-E) and wild-type
(C and E) mouse groups (Figure 1d, * p < 0.05). Thus, the Ob group presented greater
increases in blood glucose levels as compared to the C and E groups. Moreover, the Ob-E
group showed the greatest increases in blood glucose levels at 30, 60, and 120 min after
glucose administration. These were significantly different when compared to the C, E,
and Ob groups (Figure 1d, ** p < 0.05).
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Figur 1. (a) Weekly animal weights (* p < 0.05 Ob-E and Ob vs. C a ); (b) weekly basal glycemia (* p < 0.05 vs. rest of
groups, ** p < 0.05 vs. C and E); (c) blood insulin levels (* p < .05 vs. C E); (d) blood glucose levels during the glucose
overload test (%) (** p < 0.05 vs. all groups, * p < 0.05 Ob vs. C and E). , wild-type control; E, wild-type ethanol; Ob, Ob
control; Ob-E, Ob–ethanol.
2.2. Cognitive Effects of Ethanol Consumption
A novel object recognition test was used to assess short- (1 h) and long-term (24 h)
memory alterations. No significant differences were ob rved between the wil -type (C, E)
and Ob (Ob, Ob-E) groups (Figure 2).
2.3. Effects of Ethanol Intake on GR and GPx Activity
In this experiment, the enzymatic activity of brain GR and GPx was assessed. Figure 3
reflects the effects of ethanol administration on GPx and GR activity (Figure 3a,b, respec-
tively). One-way ANOVA showed significant differences in GR enzymatic activity for the
Ob-E group. Greater GR activity values were found for the Ob-E group as compared to the
rest of the groups (* p < 0.05).
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Figure 2. Effects of chronic ethanol exposure on wild-type and Ob mice in the object memory recognition task. Bars represent
the mean ± SEM of the discrimination index evaluated at 1 h (short-term memory) (a) and 24 h (long-term memory)
(b). Discrimation index is defined as DI = [(tnovel − tfamiliar)/(tnovel + tfamiliar) × 100%]. C, wild-type control; E, wild-type
ethanol; Ob, Ob control; Ob-E, Ob–ethanol.
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Figure 3. Effect of chronic ethanol exposure on enzymatic glutathione peroxidase (GPx) (a) and glutathione reductase (GR)
activity (b) in the brain. Bars represent the mean ± SEM.* p < 0.05 vs. rest of groups. C, wild-type control; E, wild-type
ethanol; Ob, Ob control; Ob-E, Ob–ethanol.
2.4. Effects of Ethanol Consumption on GSH, GSSG, GSH/GSSG Ratio, and L-Cysteine
No significant differences were observed in brain GSH levels after 6 weeks of ethanol
consumpt on (Figure 4a). One-way ANOVA showed significant differences in brain glu-
tathione disulfide (GSSG) concentrations. Post hoc comparisons indicated decreased GSSG
concentrations in the E, Ob, and Ob-E groups as compared to the C group (Figure 4b;
p < 0.05). With regard to the brain GSH/GSSG ratio, one-way ANOVA showe significant
differences for the Ob versus C groups and for the Ob-E versus E and C groups (Figure 4c;
p < 0.05). Post hoc comparisons demonstrated an increased GSH/GSSG ratio in Ob mice
when compared to the C group, and in the Ob-E group versus the C and E groups.
We also measured L-cysteine concentrations in mouse brain samples. Post hoc com-
parisons indicated increased Ob-E brain L-cysteine concentrations as compared to the C
group (Figure 4d, p < 0.05).
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3. Discussion
The results obtained in the present study showed that chronic ethanol intake im-
proved fasting glycemic values but induced impaired glucose tolerance in MS model mice.
Importantly, when measured over the time course of the experiment, no differences in
weight were observed between the MS Ob mutant and Ob-E mice. Insulin levels in the Ob
groups were significantly increased as compared to the wild-type, C, and E groups. As re-
ported in the literature, this MS genetic model is defined (among other characteristics) by
insulin resistance that leads to an altered glycemic response and hyperglycemia. Moreover,
there was an increase in GR activity, GSH/GSSG ratio, and L-cysteine levels, indicating a
compensatory mechanism due to the ethanol-elicited oxidative aggression after chronic
ethanol intake.
3.1. MS Mice Model and Chronic Ethanol Consumption
In the present study, a MS genetic mouse model was used (B6.Cg-LepOb). Use of
this model (known as Ob) is efficient because of the shortened time required for the
development of MS as compared to the diet-induced MS model. In this regard, Ob mice
are visually obese practically upon arrival and after 4 weeks of age the growing curve
changes drastically and continues to increase even after 12 months of age. These mice
have mild hyperglycemia, which transiently changes over time until sustained glucose
blood levels of around 400 mg/dL are achieved. Interestingly, it is common to find peaking
glucose elevations which result in β-cell failure. Moreover, this Ob model has elevated
plasma cholesterol levels [36,37]. The ethanol intoxication model used in this study has
been reported to achieve pharmacologically relevant blood ethanol concentrations [38,39].
Chronic ethanol consumption modulates glycemic levels and acute glycemic response.
Insulin levels within the MS groups were increased when compared to those of wild-type
animals (Figure 1c). It has been reported that chronic ethanol administration enhances
cellular insulin levels [19–22]. One of the molecular mechanisms involved relates to
an ethanol-dependent increase in intracellular cAMP levels through a Ca2+-dependent
mechanism. The intracellular calcium release elicited by ethanol may play a prominent
role as a mechanism involved in cellular insulin release [29,40] and the consequential
observed hypoglycemia. Interestingly, as mentioned above, insulin levels within the MS
groups (both Ob and Ob-E) were increased when compared to those of wild-type animals
(Figure 1c) indicating that ethanol administration did not modify the impaired cellular
insulin homeostasis of Ob mice. It is well known that β-cells compensate for the insulin
resistance characteristic of this metabolic disorder, with an increase in secretory capacity or
in beta-cell mass [36,37,40]. Moreover, insulin resistance appears to be a mechanism that
overloads β-cells. This leads to malfunction and apoptosis [41], which result in the charac-
teristic clinical manifestations of T2D: hypoinsulinemia and hyperglucagonemia [42,43].
In this respect, different mechanisms elicited by chronic ethanol administration have been
described in the regulation of beta cell function [44]. On one hand, it has been described
that chronic ethanol intake modulates glycemic levels through an increase in insulin re-
lease [19–22]. On the other hand, several authors have reported that the modulation of
glycemic levels by ethanol is linked to its positive correlation with the development of
abdominal obesity, which results in an increase in free fatty acid levels and lipogenesis.
In this regard, mechanisms such as proinflammatory adipokine activity, glucokinase dys-
regulation, or GABA receptor inhibition underlie pancreatic beta-cell dysfunction and
insulin release dysregulation [45–48]. While in our experimental conditions insulin levels
were not modified by ethanol administration, we demonstrated that the acute glycemic
response after a glucose overload worsened in the Ob-E group as compared to the Ob
group (Figure 1d). Interestingly, fasting glycemic levels in chronic ethanol-treated MS
animals were reduced to normal control values (Figure 1b). Moreover, it was also shown
that ethanol administration in wild-type animals also reduced glycemia. It is known that
ethanol metabolism inhibits gluconeogenesis and as a result, hepatic glucose production is
initially upheld by glycogenolysis. Once the hepatic glycogen stores are depleted hypo-
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glycemia may occur, explaining the late hypoglycemic effect of ethanol [49]. In addition,
ethanol-induced hypoglycemia may be associated with blunted nocturnal growth hormone
response, impaired counterregulatory response, and impaired ketogenesis [50]. Type 2
diabetes is a progressive disease which typically starts with a gradual loss of glycemic
control after meals followed by the development of fasting hyperglycemia [51,52]. Our re-
sults indicate that ethanol causes a deterioration in postprandial glucose (Figure 1d) before
fasting glucose (Figure 1b) in Ob mice. This supports the idea of a time-dependent effect
of ethanol on cellular glycemic homeostasis. Preliminary data obtained in our laboratory
demonstrated that ethanol administration to MS animals for 6 months aggravated the
glucose overload response and reduced insulin release in Ob-E mice. Further studies
are necessary to demonstrate whether this reduction is due to the overload, malfunction,
or apoptosis of β-cells characteristic of T2D.
3.2. Chronic Ethanol Consumption and MS Modulate Oxidative Status in the Brain of Mice
Postprandial hyperglycemia may induce oxidative stress [53], and central ethanol
metabolism plays a critical role in the disruption and loss of the cellular oxidative bal-
ance [54]. There is a large body of evidence indicating that at a central level, ethanol is
oxidized through a catalase–H2O2 system. This oxidative reaction results in the production
of ethanol’s first oxidative metabolite, acetaldehyde, which is highly reactive and respon-
sible for cell injury [55–58]. In our experimental conditions, we observed that ethanol
administration was able to increase brain GR activity as well as the GSH/GSSG ratio and
L-cysteine concentrations in Ob-E mice (Figure 4). These results support the hypothesis of
a compensatory mechanism after an oxidative insult based on a temporary cellular increase
in antioxidant defense to restore the original homeostatic conditions [59,60]. Due to the
formation of reactive species the glutathione system is activated to reestablish cell redox
balance. When a harmful oxidant agent is present in the cell, GPx is activated, reducing
the reactive species and oxidizing GSH to its disulfide form (GSSG). Thus, GSSG is re-
duced to GSH through GR enzyme activity, restoring initial GSH concentrations. In this
process, GSH and its disulfide form GSSG remain in constant enzyme substrate turnover.
Our data showed an increase in GR activity which was not accompanied an enhanced
GPx activity, thus justifying the reduced GSSG concentration and increased GSH/GSSG
ratio. Other studies have found an increase in the enzymatic activity of GPx after ethanol
administration [61,62]. This discrepancy may be due to the fact that these studies explored
the acute effects of ethanol administration. There is a large body of evidence indicating
that in the brain, acetaldehyde is directly formed via the catalase–H2O2 system [54]. In this
respect it may be hypothesized that after 6 weeks of ethanol administration GPx activity
does not increase because its substrate, H2O2, appears to be reduced by the catalase sys-
tem. Moreover, we observed an increase in brain L-cysteine concentrations in the Ob-E
group (Figure 4). The increase in levels of this antioxidant supports the hypothesis of a
compensatory mechanism [63]. Thus, in animals with MS, chronic ethanol administration
modulates GSH metabolism, resulting in elevated concentrations of at least one of its
forming peptides.
With respect to brain MDA concentrations, lipid peroxidation is a process which
involves the oxidation of polyunsaturated fatty acids present in the biological membranes.
The products of this lipid peroxidation (such as MDA) yield several DNA adducts, are
extremely mutagenic, and cause protein damage [64–66]. It has been demonstrated that
lipid peroxidation can be increased by ethanol administration, which is accompanied by
diminished cell antioxidant defense [67,68]. However, in our experimental conditions this
ethanol-induced peroxidative damage appeared to be offset by the increased response of
the cellular antioxidant system (Figures 3 and 4).
3.3. Behavioral Effects of Chronic Ethanol Consumption in MS Mice
At the behavioral level, 6 weeks of chronic ethanol administration modulated different
processes involved in glucose homeostasis, acute glycemic response, and brain oxidative
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status, but did not have behavioral effects in our model of MS. In this respect, different
authors have found behavioral alterations within the same time-course of ethanol ad-
ministration. However, the experimental procedure used to obtain the effects of ethanol
intoxication was based on a different diet (Lieber-de-Carli) [67]. Thus, in our experimental
conditions, short- and long-term recognition memory processes were not affected. In fact,
this ethanol administration model was proven to produce behavioral impairment after
5 months of ethanol consumption [38,39].
4. Materials and Methods
4.1. Animals
A total of 96 male C57BL6 and B6.Cg-LepOb (Janvier Labs, Le Genest-Saint-Isle, France)
mice were used in this study. The animals, which were 4 weeks of age upon arrival,
were housed five per cage in an acclimated quarantine room in which they remained for a
week. After this period, mice were moved into the colony room for a week before ethanol
exposure. Mice were 6 weeks of age when ethanol was introduced for 6 weeks. The colony
room was maintained at a temperature of 21± 1 ◦C, and controlled under a 12-h light/dark
cycle (lights on at 8:00 a.m.). Food and water were provided ad libitum throughout the
study. All experimental procedures complied with the European Community Council Di-
rective (2010/63/EU) and were approved by the Animal Health department of Generalitat
Valenciana (project code: 2019/VSC/PEA/0053, approved date: 11 March 2019).
4.2. Drugs and Chemicals
Ethanol (Panreac, Barcelona, Spain) was diluted to 12% (v/v) in water and administered.
To prepare working solutions and assay reactants potassium hydrogenphophate,
potassium dihydrogenphosphate, glutathione oxidized, glutathione reduced, L-cysteine,
1-fluoro-2,4-dinitrobencene, iodoacetic acid, perclhoric acid, glacial acetic acid, sodium
acetate, ethylenediaminetetraacetic acid (EDTA), sodium azide (NaN3), GSH disulfide
reductase (GR), hydrogen peroxide 30%, 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB),
sodium hydrogenphophate, sodium dihydrogenphosphate, 2-thiobarbituric acid and
1,1,3,3-tetramethoxypropane were purchased from Sigma-Aldrich (Darmstadt, Germany).
Methanol and NADPH were purchased from Scharlab (Barcelona, Spain) and Panreac
(Barcelona, Spain), respectively. High-purity water was obtained from a Millipore System
(Merk Millipore, Burlington, MA, USA).
4.3. Experimental Procedure
Animals were divided into four groups (n = 10–12 per group): wild-type control (C),
wild-type ethanol (E), MS control (Ob), and MS ethanol (Ob-E). The E and Ob-E groups
were exposed to ethanol (12% v/v) in drinking water for 6 weeks. To avoid treatment
rejection, the ethanol concentration was scaled over a 2-week habituation period (0%, 2%,
4%, 6%, 8%, 10%, and 12%, every 48 h). The blood ethanol levels achieved in the E and
Ob-E groups were 108.5 ± 18.0 mg/dL and 95.6 ± 22.6 mg/dL, respectively.
Weight, glycemia, and liquid consumption values were determined once a week, 2 h
after lights were turned on. Animals were moved from their home cages to the procedure
room 30 min before the start of each experiment, allowing them to acclimatize to the
environmental conditions. Finally, animals were sacrificed using cervical dislocation.
Blood samples and brain samples were frozen to −80 ◦C for further analysis. Prior to
freezing, brain samples were homogenized in prechilled 0.2 M potassium phosphate buffer,
pH 7.
4.3.1. Glycemia, Insulinemia, and Glucose Overload Tests
Glycemia was measured weekly through the collection of 1 µL of blood from the
mouse tail. Glucose levels were then measured using an ACCU-CHECK glucometer
(Roche Diagnostics, Rotkreuz, Switzerland). Blood insulin levels were assayed using an
Elisa Kit (Merk, Darmstad, Germany). For the glucose overload test, fasting mice (12 h)
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were treated with glucose (2 g/kg i.p.), and blood glucose levels were determined after
30, 60, and 120 min. Glycemic values at 30, 60, and 120 min were represented as a % of
increase versus time 0.
4.3.2. Memory and Learning Test
Short- and long-term memory, as well as the behavioral effects of ethanol,
were evaluated using the object recognition test. Briefly, a 40-cm diameter cylinder with
sawdust on the floor was set down in a testing room with faint light. Two red plastic
blocks were placed inside the cylinder and a mouse was allowed to inspect objects for
5 min (training session). To measure short-term memory, one of the blocks was changed
to a round yellow block. All the objects were heavy enough to prevent displacement.
One hour after the end of the training session animals were placed in the middle of the
cylinder and allowed to explore the objects for 5 min to evaluate short-term memory.
The experiment was repeated 24 h after the end of the training session to evaluate long-
term memory. The orientation of the animal’s snout toward the object within a range of
2 cm or less from the object was defined as object exploration. Sitting on the object or
running around it was not recorded as exploration. Objects were washed with ethanol
after each individual trail to equate olfactory cues. The discrimination index, calculated
as [DI = (tnovel − tfamiliar)/(tnovel + tfamiliar) × 100%], was used as a basic measure in the
object recognition test [38].
The oxidative status of brain samples was evaluated as follows:
4.3.3. Antioxidant Defenses
Glutathione (L-Glutamyl-L-cysteinyl-glycine) is a tripeptide with multiple cellular
functions. Glutathione is the main antioxidant system in the cell and a detoxification agent
for ROS and reactive nitrogen species. There are two forms of glutathione: the oxidized
form (GSSG) and the reduced form (GSH). The GSH/GSSG redox couple is a cosubstrate
for glutathione peroxidase and reductase enzymes (GPx and GR) which act as a vital
cellular redox buffer modulating different sensitive biochemical and biophysical processes.
L-cysteine is a glutathione biosynthesis precursor used as an oxidative stress biomarker [69].
GSH, GSSG, and L-Cysteine
GSH, GSSG, and L-cysteine concentrations were chromatographically quantified
using Reed’s method [70]. This method derivatizes the amino groups with 1-fluoro-2,4-
dinitrobencene (Sanger reactant) after blocking the free thiol groups with iodoacetic acid.
Briefly, samples (180 µL with 20 µL perclhoric acid 20%) were centrifuged, and then
iodoacetid acid (40 µL, 0.1 M) was added. After adjusting to pH 9 and with obscurity
and ice-cold incubation for 30 min, Sanger reactant (200 µL) was added. Samples were
then incubated overnight at 4 ◦C. Samples were centrifuged and filtered through a 22-µm
nylon filter prior to the chromatographic analysis. The high-performance liquid chromatog-
raphy (HPLC) working solutions were methanol:water (4:1, v/v) (mobile phase A) and
methanol:sodium acetate buffer 3.45 M pH 5.3 (64:36, v/v) (mobile phase B). Separation
was carried out using a Kromasyl-NH2 250 × 4.6 mm 5 µm column (Waters Corporation,
Mildford, MA, USA), and the UV-Vis detector was set at 365 nm. The separation gradient
was 20% B from initial time to 10 min, which was then increased linearly to 80% B at 45 min
at a 1 mL/min flow.
Glutathione Peroxidase Activity (GPx)
GPx was measured by monitoring the disappearance of NADPH at 340 nm [71].
Briefly, 50-µL samples were mixed with potassium phosphate buffer 0.1 M pH 7.0 (550 µL)
containing ethylenediaminetetraacetic acid (EDTA), NaN3 (both 1 mM), and 100 µL of the
following solutions: GSH disulfide reductase (0.24 U/mL), reduced glutathione (1 mM),
and NADPH (0.15 mM). After incubation (3 min at 37 ◦C), a reaction was started by the
addition of hydrogen peroxide 1.5 mM (100 µL).
Int. J. Mol. Sci. 2021, 22, 807 10 of 14
Glutathione Reductase Activity (GR)
GR was determined spectrophotometrically using Smith’s proposed method [72].
Briefly, when the GR catalyzed reduction of GSSG to GSH was produced in presence of
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), 2-nitrobenzoic acid was formed as a subproduct.
Formation was monitored at 412 nm. The GSSG reduction was started by adding 25 µL of
brain sample to a solution containing DTNB 3 mM prepared in 10 mM sodium phosphate
buffer, 2 mM NADPH, and 10 mM EDTA in 0.2 M pH 7.5 sodium phosphate buffer.
The oxidative damage to macromolecules was evaluated as follows:
Lipid peroxidation or reaction of oxygen with unsaturated lipids produces a wide
variety of oxidation products. One of the main primary products and a biomarker for lipid
peroxidation is MDA, which appears to be the most mutagenic and cell-toxic agent [73].
4.3.4. Lipid Peroxidation
MDA concentrations were determined chromatographically using an HPLC system
equipped with a fluorescence detector (set to 527 nm for excitation and 532 nm for emission).
Sample preparation consisted of mixing samples (100 µL) with 0.75 mL of thiobarbituric
acid 0.37% and perchloric acid 6.4% (2:1, v/v), heating to 95 ◦C for an hour. Prior to injection
in the HPLC system, the pH was adjusted to 6 and precipitates were removed by centrifu-
gation (10,000 rpm, 1 min). Separation was carried out in a C18 250 × 4.6 mm 5 µm column
(Scharlab, Barcelona, Spain) and flow was set at 1 mL/min in an isocratic separation.
Mobile phase consisted of a 50-mM potassium phosphate buffer (pH 6.0):methanol (58:42,
v/v). Standard solutions were prepared daily from 1,1,3,3-tetramethoxypropane.
This method was first proposed by Richard [74] and later modified by Romero and cols. [75].
4.3.5. Protein Content
Protein levels were determined from brain lysates in accordance with the method
described by Bradford [76] (ThermoFisher Scientific, Waltham, MA, USA).
4.3.6. Statistical Analysis
Statistical analyses were carried out using SPSS software (IBM SPSS Statistics for
Windows, Version 25.0 IBM Corp, Armonk, NY, USA). Results were presented as mean
values ± SE. Comparisons between groups were made by one-way ANOVA. The analysis
of variance of the obtained data was performed by the Levene test, using the LSD test
as a post hoc test when the data showed homogeneity in their variances (p < 0.05), or a
Dunnet T3 test when variances differed. Statistical significance differences were set at the
p < 0.05 level.
5. Conclusions
This body of evidence supports the hypothesis that ethanol is a modulating agent of
glycemic response in MS mice. This modulation was accompanied by a dysregulation of the
brain oxidative status but did not affect short- and long-term memory, indicating moderate
effects of ethanol consumption on behavior. However, further studies are required to
elucidate the particular mechanisms by which ethanol might modulate the transition from
MS to T2D.
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